Ziopharm bulls bet on explosive move
Jon "DRJ" Najarian | firstname.lastname@example.org
optionMONSTER's Heat Seeker program showed heavy buying in the May 7 calls, including one big block of 3,500 contracts for $0.70. Open interest was a mere 145 contracts coming in today, so someone obviously believes that this $245,000 investment will yield big returns.
Long calls lock in the price investors must pay to buy a stock. They can generate nice leverage in the event of a rally but will expire worthless if the shares climb above the $7 strike price by mid-May. (See our Education section)
Ziopharm began the week as a $4 stock. Now, after a presentation at an industry conference and Phase III trials of Palifosfamide treatment on soft-tissue sarcoma looking extremely positive, shares are closer to $5.
Palifosfamide belongs to a group of chemotherapy drugs called alkylating agents, which halt tumor growth by binding to cancer-cell DNA and interfering with its function. Full results are expected by the end of this quarter.
ZIOP ended yesterday's session up 0.21 percent to $4.70. Calls dominated its option activity, outnumbering puts by a bullish 15-to-1 ratio.
Disclosure: I own ZIOP call spreads.
(A version of this post appeared on InsideOptions Pro yesterday.)